The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
Figures show Britain has a pothole problem of epidemic proportions as it is revealed £9.3 billion would be needed to repair all roads.
Cambridge Analytica say allegations against Alexander Nix do not represent the values or operations of the firm.
Republican Senator and former presidential nominee, John McCain has blasted Trump calling Putin's victory "a sham election".